Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.
about
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu statusChromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasHER2 testing: a review of detection methodologies and their clinical performanceDetermination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinomaHER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains.Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas.Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer.
P2860
Q21195160-BA2C84B3-5209-44C6-8175-A790655D33BFQ26865068-90BECC4E-CAFF-42B9-A41D-7B199EE611DFQ28280488-D27C7820-6B9B-47E7-A3C8-32030DEC3B23Q31078568-9E6A77C6-C20F-4CF2-B381-EE6341B2350DQ33421127-197D2997-6CB8-47AA-B310-3472FE038572Q33631562-201C6D17-F8F9-4822-854B-BB4ACB0CC515Q34424833-C51BFBF2-3998-427B-8993-79C26B4E3C71Q35984457-26D3C77D-435C-4DC8-A22B-8AB9482D6E60Q39978523-8AFB5400-6AB3-44ED-8031-B9E28B2F1C79Q50767143-3217BBA1-D4EF-40D8-A623-78B51C1FD79FQ52976761-ADB3C5E9-3826-49B5-BFEA-243C5F100672Q53126969-4335D77C-34C1-429F-93B6-832926EBEF73Q55053588-48C6AEA0-B65A-4682-96DF-31120669640B
P2860
Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@ast
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@en
Chromogenic in situ hybridizat ...... ng of patients for trastuzumab
@nl
type
label
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@ast
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@en
Chromogenic in situ hybridizat ...... ng of patients for trastuzumab
@nl
prefLabel
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@ast
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@en
Chromogenic in situ hybridizat ...... ng of patients for trastuzumab
@nl
P2093
P2860
P1476
Chromogenic in situ hybridizat ...... astuzumab (Herceptin) therapy.
@en
P2093
Ichinohasama R
Kumamoto H
Taniguchi T
P2860
P304
P356
10.1046/J.1440-1827.2001.01255.X
P577
2001-08-01T00:00:00Z